standards > reporting guideline > DOI:10.25504/FAIRsharing.zgwrmg


ready Minimum Information Model for tolAPC

Abbreviation: MITAP


General Information
The minimum information model for tolAPC (MITAP) guideline is an initiative of members of the tolAPC field to provide a reporting framework that will make differences and similarities between tolAPC products transparent. Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.

Homepage https://doi.org/10.7717/peerj.2300

Countries that developed this resource Belgium , Chile , France , Germany , Italy , Netherlands , Norway , Republic of Ireland , Serbia , Spain , Turkey , United Kingdom , United States

Created in 2016

Taxonomic range




How to cite this record FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 17 2021 6:22 a.m.


This record is maintained by phillord

Record added: Nov. 9, 2016, 1:36 p.m.
Record updated: Nov. 15, 2016, 2:20 p.m. by The FAIRsharing Team.

Show edit history


In Collections
RDA Covid-19 WG Resources


Support

General

online documentation https://ia600500.us.archive.org/33/items ...

Additional Information

Contact catharien.hilkens@newcastle.ac.uk

Tools

    No tools defined


Schemas

No XSD schemas defined


Access / Retrieve Data

Conditions of Use





Publications

Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies.

Lord P,Spiering R,Aguillon JC,Anderson AE,Appel S,Benitez-Ribas D,Ten Brinke A,Broere F,Cools N,Cuturi MC,Diboll J,Geissler EK,Giannoukakis N,Gregori S,van Ham SM,Lattimer S,Marshall L,Harry RA,Hutchinson JA,Isaacs JD,Joosten I,van Kooten C,Lopez Diaz de Cerio A,Nikolic T,Oral HB,Sofronic-Milosavljevic L,Ritter T,Riquelme P,Thomson AW,Trucco M,Vives-Pi M,Martinez-Caceres EM,Hilkens CM
PeerJ 2016

View Paper (PubMed) View Publication

Related Standards

Reporting Guidelines

No guidelines defined

Terminology Artifacts

No semantic standards defined

Models and Formats

No syntax standards defined

Identifier Schemas

No identifier schema standards defined

Metrics

No metrics standards defined


Related Databases (0)

No Related Databases


Implementing Policies

This record is not implemented by any policy.


Credit

Record Maintainer

Funds

Grant Number(s)